ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel…
Continue Reading-
Complement Therapeutics Secures €72 Million in Series A Financing
Complement Therapeutics Secures €72 Million in Series A Financing...
Continue Reading -
Alex Therapeutics extends financing round to €4.75M with leading life science VC
Innovestor Life Science, a leading biotech and digital health VC, invests €1.25M in the digital…
Continue Reading -
Alex Therapeutics and Vicore Pharma today announce the first study subject enrolled in the pivotal study COMPANION evaluating Almee™
Stockholm, 5th December 2022 — Alex Therapeutics and Vicore Pharma today announce the first study…
Continue Reading -
Step Pharma Announces First Patient Dosed with STP938, the World’s Most Advanced CTPS1 Inhibitor, in a Phase 1/2 Trial for T cell and B cell lymphomas
Step Pharma Announces First Patient Dosed with STP938, the World’s Most Advanced CTPS1 Inhibitor, in…
Continue Reading -
Gesynta Pharma prepares Phase II study of GS-248 in endometriosis following ground-breaking data from a preclinical proof-of-concept study
Gesynta Pharma prepares Phase II study of GS-248 in endometriosis following ground-breaking data from a…
Continue Reading -
Alex Therapeutics presents results from digital therapeutic pilot study showing nearly 50% reduction in anxiety
The Digital Therapeutic (DTx) was developed by DTx leader Alex Therapeutics using the proprietary “Alex…
Continue Reading -
Cardior Announces First Patient Dosed in Phase 2 Study
Cardior Announces First Patient Dosed in Phase 2 Study Evaluating Efficacy and Safety of Non-coding…
Continue Reading -
Gesynta Pharma completes patient enrollment in its Phase II study in systemic sclerosis
Stockholm, Sweden, 12 July 2022 – Gesynta Pharma AB today announces that all patients have…
Continue Reading -
Attgeno AB announces fully subscribed share issue to complete clinical phase II study in acute pulmonary hypertension
Attgeno AB announces that a successful share issue was completed at midsummer 2022 and resulted…
Continue Reading